SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes on Monday, May 11, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 6043504. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under . A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 6043504.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit .

EN
04/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sangamo Therapeutics Inc.

 PRESS RELEASE

Sangamo Therapeutics Reports Recent Business Highlights and Second Qua...

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticip...

 PRESS RELEASE

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should reg...

 PRESS RELEASE

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Qua...

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2024 financial results. “I am pleased with Sangamo’s pipeline progress since the start of 2024. We advanced our two prioritized neurology therapies towards the clinic, securing our first ever neurology IND; we showed we are a collaborator of choice for neurotropic capsids, with the announcement of two blue-chip pharma agreements for our STAC-BBB capsid, with negotiations advancing for a third potential agreement; ...

 PRESS RELEASE

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earni...

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference. Fourth Quarter and Full Year 2024 Earnings Results The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the co...

 PRESS RELEASE

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in F...

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. Updated data continue to support the potential of isaralgagene civaparvovec as a one-time, durable treatment option for Fabry disease that can improve patient outcomes. These data will be presented at the 21st Annual WORLDSymposiumTM in San Diego, CA on February 6, 2025, in an oral presentation in t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch